argenx SE's latest marketcap:
As of 06/18/2025, argenx SE's market capitalization has reached $33.27 B. According to our data, argenx SE is the 644th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 33.27 B |
| Revenue (ttm) | 2.64 B |
| Net Income (ttm) | 1.06 B |
| Shares Out | 60.98 M |
| EPS (ttm) | 15.94 |
| Forward PE | 34.82 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/24/2025 |
argenx SE's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/18/2025 | $33.27 B | -4.52% | 644 |
| 12/31/2024 | $36.77 B | 72.75% | 541 |
| 12/29/2023 | $21.29 B | 2.05% | 843 |
| 12/30/2022 | $20.86 B | 15.89% | 791 |
| 12/31/2021 | $18 B | 29.92% | 1101 |
| 12/31/2020 | $13.85 B | 126.49% | 1214 |
| 12/31/2019 | $6.12 B | 96.21% | 2035 |
| 12/31/2018 | $3.12 B | 83.75% | 2940 |
| 12/29/2017 | $1.7 B | 5101 |
Company Profile
About argenx SE
argenx SE is a commercial-stage biopharmaceutical company focused on developing innovative therapies for autoimmune diseases. Operating globally, including in the United States, Japan, China, and the Netherlands, the company is dedicated to advancing treatments for patients with severe autoimmune conditions.
Key Products & Therapies
- VYGART & VYGART HYTRULO – Treatments for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).
- Efgartigimod – Investigational therapy for seronegative/ocular gMG, thyroid eye disease, ITP, myositis, Sjögren’s disease, lupus nephropathy, and other autoimmune disorders.
- Empasiprubart – Targets multifocal motor neuropathy, CIDP, delayed graft function, and dermatomyositis.
- ARGX-119 – A MuSK agonist for congenital myasthenic syndromes, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy.
Pipeline & Research
argenx is advancing a diverse pipeline of experimental therapies, including:
- ARGX-109 – Targets IL-6 to reduce inflammation.
- ARGX-121 & ARGX-220 – Immune system modulators.
- ARGX-213 – Focused on FcRn inhibition.
- ARGX-118 – Antibodies against Galectin-10.
- Additional candidates: cusatuzumab, ARGX-112, ARGX-114, ARGX-115.
Strategic Collaborations
The company partners with leading institutions and biopharma firms, including:
- OncoVerity, Inc.
- LEO Pharma A/S
- Zai Lab Limited
- AbbVie, Inc.
- Genmab SE
- Chugai Pharmaceutical Co., Ltd.
Founded: 2008 | Headquarters: Amsterdam, the Netherlands
Frequently Asked Questions
-
What is argenx SE's (ARGX) current market cap?As of 06/18/2025, argenx SE (including the parent company, if applicable) has an estimated market capitalization of $33.27 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does argenx SE (ARGX) rank globally by market cap?argenx SE global market capitalization ranking is approximately 644 as of 06/18/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.